Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;170(5):623-626.
doi: 10.1007/s10517-021-05119-1. Epub 2021 Mar 31.

Pharmacological Correction of Cisplatin-Induced Hemostatic Disorders

M V Filonova  1   2 , E P Fedorova  3 , A A Churin  3   4 , L Yu Kotlovskaya  3   4 , M A Solov'ev  3 , V V Udut  3   4
Affiliations

Pharmacological Correction of Cisplatin-Induced Hemostatic Disorders

M V Filonova et al. Bull Exp Biol Med. 2021 Mar.

Abstract

A single intraperitoneal administration of cisplatin in the MTD to outbred female mice disturbed hemostasis and formed the procoagulant phenotype of hemostatic potential on days 7-10 culminating in a pronounced hypocoagulation on day 15. Hemostasis was corrected with warfarin and an extract containing furocoumarins composed of isopimpinellin (42.97%), bergapten (35.18%), and xanthotoxin (15.41%). The extract was standardized with gas chromatography-mass spectrometry, thin-layer chromatography, and HPLC. Furocoumarins and reference drug warfarin were administered intragastrically during 4 days starting on day 6 after the administration of cisplatin. Both furocoumarins and warfarin corrected hypercoagulation on days 7-10. On day 10, furocoumarins normalized coagulation, whereas warfarin resulted in hypocoagulation. On days 15-30, no effects of warfarin were observed. furocoumarins corrected hypocoagulation on days 15-20 with prolongation of this effect up to experimental day 30.

Keywords: cisplatin; furocoumarins; hemostatic potential; low-frequency piezothromboelastography; outbred mice.

PubMed Disclaimer

References

    1. Filonova MV, Fedorova YS, Beregovykh GV, Churin AA. Patent RU No. 2713118. Method for extracting the sum of furocoumarins from cell culture of hemlock patchy (Conium maculatum L.). Bull. No. 4. Published February 3, 2020.
    1. Bruni R, Barreca D, Protti M, Brighenti V, Righetti L, Anceschi L, Mercolini L, Benvenuti S, Gattuso G, Pellati F. Botanical sources, chemistry, analysis, and biological activity of furanocoumarins of pharmaceutical interest. Molecules. 2019;24(11):2163. https://doi.org/10.3390/molecules24112163 - DOI - PMC
    1. Chiang SR, Lin CS, Lin HH, Shieh PC, Kao SH. Bergapten induces G1 arrest of non-small cell lung cancer cells, associated with the p53-mediated cascade. Mol. Med. Rep. 2019;19(3):1972-1978. https://doi.org/10.3892/mmr.2019.9810 - DOI - PubMed
    1. Dehghan H, Sarrafi Y, Salehi P, Ebrahimi SN. α-Glucosidase inhibitory and antioxidant activity of furanocoumarins from Heracleum persicum. Med. Chem. Res. 2017;26(4):849-855. https://doi.org/10.1007/s00044-017-1796-y - DOI
    1. Fehr M, Hawle H, Hayoz S, Thuss-Patience P, Schacher S, Riera Knorrenschild J, Dürr D, Knoefel WT, Rumpold H, Bitzer M, Zweifel M, Samaras P, Mey U, Küng M, Winterhalder R, Eisterer W, Hess V, Gérard MA, Templeton A, Stahl M, Ruhstaller T; Swiss Group for Clinical Cancer Research (SAKK); German Esophageal Cancer Study Group; Austrian Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT); Fédération Francophone de Cancérologie Digestive (FFCD) / Fédération de Recherche en Chirurgie (FRENCH). High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. BMC Cancer. 2020;20(1):166. https://doi.org/10.1186/s12885-020-6623-zz

LinkOut - more resources